Furiex Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Morrisville NC United States (1998)
Status: Acquired by Forest Laboratories (2014) → now AbbVie (2019)

Organization Overview

First Clinical Trial
2010
NCT01130272
First Marketed Drug
2015
eluxadoline (viberzi)
First NDA Approval
2015
eluxadoline (viberzi)
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Furiex Pharmaceuticals, Inc

Active Ingredients

Marketed Drugs (1)

eluxadoline (viberzi) (2015 NDA)

Drugs in Phase 3 Trials (1)

eluxadoline (viberzi) (3 trials)

Drugs in Phase 2 Trials (5)

Acorafloxacin (2 trials)

atorvastatin (lipitor) (1 trial)

linezolid (zyvox) (1 trial)

moxifloxacin (avelox) (1 trial)

ppd10558 (1 trial)

Indications

Approved Indications


 

Irritable Bowel Syndrome

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Diarrhea (Phase 3)

Hypercholesterolemia (Phase 2)

Hyperlipidemias (Phase 2)

Hyperlipoproteinemias (Phase 2)

Infections (Phase 2)

Irritable Bowel Syndrome (Phase 3)

Myalgia (Phase 2)

Pneumonia (Phase 2)

Pneumonia, Bacterial (Phase 2)

Skin Diseases, Bacterial (Phase 2)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 6
  • # of Trial APIs: 6